DDInter202 DDInter1676
Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Bexarotene {u} (Compound) resembles {v} (Compound) Tamibarotene
Bexarotene {u} (Compound) treats {v} (Disease) hematologic cancer
Bexarotene {u} (Compound) binds {v} (Gene) RXRG
Bexarotene {u} (Compound) is included by {v} (Pharmacologic Class) Retinoids
Bexarotene {u} (Compound) causes {v} (Side Effect) Hypocholesterolaemia
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Griseofulvin
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palifermin
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amlodipine
Bexarotene {u} may lead to a major life threatening interaction when taken with {v} Cytarabine
Bexarotene (Compound) resembles Tamibarotene (Compound)
Bexarotene (Compound) treats hematologic cancer (Disease)
Bexarotene (Compound) binds RXRG (Gene)
Bexarotene (Compound) is included by Retinoids (Pharmacologic Class)
Bexarotene (Compound) causes Hypocholesterolaemia (Side Effect)
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Griseofulvin
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Palifermin
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Amlodipine
Bexarotene may lead to a major life threatening interaction when taken with Cytarabine